BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
The information set forth under Item 5.02 of this Current Report on Form8-K is incorporated by reference herein.
|
Item 5.02. |
Financial Statements and Exhibits. |
(d) Exhibits
This Current Report on Form 8-K is being filed to file as exhibits the following new form of award agreements approved by the Compensation and Management Development Committee of the Board of Directors of Bristol-Myers Squibb Company (“Bristol-Myers Squibb”) under Bristol-Myers Squibb’s 2012 Stock Award and Incentive Plan, in connection with the regular annual compensation cycle of Bristol-Myers Squibb:
|
10.1 |
Form of 2019-2021 Performance Share Units Award Agreement under Bristol-Myers Squibb Company’s 2012 Stock Award and Incentive Plan |
|
10.2 |
Form of Market Share Units Agreement under Bristol-Myers Squibb Company’s 2012 Stock Award and Incentive Plan |
|
10.3 |
Form of Restricted Stock Units Agreement with one-year cliff vesting with a two-year post-vest holding period under Bristol-Myers Squibb Company’s 2012 Stock Award and Incentive Plan |
|
10.4 |
Form of Restricted Stock Units Agreement with two-year cliff vesting with a one-year post-vest holding period under Bristol-Myers Squibb Company’s 2012 Stock Award and Incentive Plan |
|
10.5 |
Form of Restricted Stock Units Agreement with five year vesting under Bristol-Myers Squibb Company’s 2012 Stock Award and Incentive Plan |
|
10.6 |
Form of Restricted Stock Units Agreement with four year vesting under Bristol-Myers Squibb Company’s 2012 Stock Award and Incentive Plan |
EXHIBIT INDEX
|
Form of 2019-2021 Performance Share Units Award Agreement under Bristol-Myers Squibb Company’s 2012 Stock Award and Incentive Plan |
|
Form of Market Share Units Agreement under Bristol-Myers Squibb Company’s 2012 Stock Award and Incentive Plan |
|
Form of Restricted Stock Units Agreement with one-year cliff vesting with a two-year post-vest holding period under Bristol-Myers Squibb Company’s 2012 Stock Award and Incentive Plan |
|
Form of Restricted Stock Units Agreement with two-year cliff vesting with a one-year post-vest holding period under Bristol-Myers Squibb Company’s 2012 Stock Award and Incentive Plan |
|
Form of Restricted Stock Units Agreement with five year vesting under Bristol-Myers Squibb Company’s 2012 Stock Award and Incentive Plan |
|
Form of Restricted Stock Units Agreement with four year vesting under Bristol-Myers Squibb Company’s 2012 Stock Award and Incentive Plan |
BRISTOL MYERS SQUIBB CO Exhibit
EX-10.1 2 s002621x29_ex10-1.htm FORM OF 2019-2021 PERFORMANCE SHARE UNITS AWARD AGREEMENT UNDER BRISTOL-MYERS SQUIBB COMPANY’S 2012 STOCK AWARD AND INCENTIVE PLAN Exhibit 10.1 PERFORMANCE SHARE UNITS AGREEMENT Under the Bristol-Myers Squibb Company 2012 Stock Award and Incentive Plan 2019-2021 Performance Share Units Award BRISTOL-MYERS SQUIBB COMPANY,…
To view the full exhibit click here
About BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP)
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its late-stage investigational compounds that are in Phase III clinical trials include Beclabuvir, BMS-663068 and Prostvac.
